Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Radiopharm Theranostics Limited ( (AU:RAD) ) has provided an announcement.
Radiopharm Theranostics Limited has announced a target market determination for attaching options related to a share offer under a prospectus dated October 20, 2025. The offer is aimed at investors seeking exposure to the radiopharmaceutical sector, with potential for capital growth and inclusion in a diversified portfolio. The attaching options are designed for those with a medium to long-term investment timeframe and the financial capacity to handle the speculative nature of the investment. The offer is managed by Bell Potter Securities Limited and is available to eligible shareholders in Australia and New Zealand.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the radiopharmaceutical sector, focusing on the development of radiopharmaceutical products. The company is involved in offering shares through a Share Purchase Plan under a prospectus, with a market focus on investors interested in capital growth within this industry.
Average Trading Volume: 4,552,171
Technical Sentiment Signal: Buy
Current Market Cap: A$87.5M
See more data about RAD stock on TipRanks’ Stock Analysis page.